ESR1 and breast cancer: Corroborating this notion, CYP2D6 polymorphisms responsible for reduced CYP2D6 activity were associated with worse breast cancer outcomes in postmenopausal estrogen receptor-positive patients treated with tamoxifen (Goetz et al., 2005).